Customizable, GMP-Compliant Medium Chain Triglycerides for Global Pharma & Nutraceutical Clients

Guangzhou, China – 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading Chinese supplier of high-end pharmaceutical lipid excipients and APIs, today announces the launch of small-batch procurement services for its domestically manufactured medium chain triglyceride (MCT) raw materials. This service addresses the unmet demand of global pharma, nutraceutical, and research clients for flexible, cost-effective access to high-purity MCT, eliminating reliance on imported supplies. Hanfang’s MCT, a breakthrough product that broke long-term foreign monopoly in 2022-2023, offers 99% purity and meets strict international quality standards. Small-batch orders start from 5kg, with fast delivery to over 30 countries worldwide.

Core Product & Technical Advantages

Hanfang’s MCT is produced via its proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatography to replace traditional polluting processes. This ensures consistent 99% purity, low impurity levels, and compliance with global pharmaceutical-grade standards. The product solves key pain points for clients, including supply chain instability from imported MCT and high minimum order quantities that hinder small-scale R&D and production. Small-batch procurement allows clients to test formulations, conduct clinical trials, or fulfill limited production runs without overstocking.

Global Compliance & Certifications

To meet global market access requirements, Hanfang’s MCT has obtained multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications confirm the product’s adherence to strict GMP, ICH, and regional regulatory standards, enabling seamless entry into major markets across Europe, North America, Asia-Pacific, and the Middle East.

Supply & Customization Services

Small-batch MCT orders are now available for global booking via Hanfang’s official website, authorized distributors, and B2B platforms. Delivery lead times are 7-14 business days for most regions, with flexible payment terms for qualified clients. Beyond standard MCT, Hanfang offers customized processing services, including tailored purity levels, packaging specifications, and formulation support to meet specific client needs. This flexible service model caters to pharma R&D labs, nutraceutical startups, and small-scale manufacturers.

Executive Quote

"The launch of small-batch MCT procurement services reflects our commitment to addressing diverse client needs and advancing global pharmaceutical supply chain resilience," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Hanfang Pharmaceutical Company Limited. "Our domestically produced MCT not only breaks foreign monopoly but also provides flexible, reliable access to high-quality raw materials for clients of all sizes, supporting their innovation and production goals."

Industry Context & Strategic Alignment

According to global pharmaceutical market reports, demand for high-purity MCT is growing at a CAGR of 6.2% due to its wide application in injectable formulations, nutraceuticals, and special medical foods. Many small and medium-sized clients face barriers to accessing imported MCT due to high MOQs and supply chain delays. Hanfang’s small-batch service fills this gap, aligning with its strategic goal of becoming a trusted global health guardian.

About Guangzhou Hanfang Pharmaceutical Company Limited

Established in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a state-owned, tech-driven pharmaceutical enterprise under the GPHL Group, a Fortune Global 500 company. It is a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, housing the only national engineering research center for traditional Chinese medicine (TCM) process technology and new drug development. The company specializes in high-end pharmaceutical lipid excipients, APIs, health products, and technical services, with over 240 patents and products sold in more than 30 countries. Its mission is to advance self-reliance in biomedical technology and safeguard global health. For more information, visit http://byshanhanfang.com/

Contact Information

Company: Guangzhou Hanfang Pharmaceutical Company Limited
Official Website: http://byshanhanfang.com/
Marketing Inquiries: [email protected]

© 2026 Guangzhou Hanfang Pharmaceutical Company Limited. All rights reserved. This release is for informational purposes only and does not constitute an offer to sell or a solicitation to buy any products.